UBS

$36.73-0.63 (-1.69%)

Market ClosedAs of Mar 20, 8:00 PM UTC

UBS Group AG provides financial advice and solutions to private, institutional, and corporate clients worldwide.

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JPMBACGS

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$36.73
Potential Upside
24.6%
Whystock Fair Value$45.77
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorFinancial Services
IndustryBanks-Diversified

UBS Group AG provides financial advice and solutions to private, institutional, and corporate clients worldwide. It operates through five divisions: Global Wealth Management, Personal & Corporate Banking, Asset Management, Investment Bank, and Non-co...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$116.05B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
15.56
Beta
Defensive asset. Lower volatility than the S&P 500.
0.82
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
6.96%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
-

Recent News

Simply Wall St.
Mar 21, 2026

How The RxSight (RXST) Investment Story Is Shifting With New Guidance And CFO Transition

RxSight’s updated fair value estimate has shifted from US$10.17 to US$10.06, a small adjustment that signals a slightly more restrained price target without a major reset. Analysts tying this move to the new 2026 revenue guidance of US$120.0m to US$135.0m, recent Q4 updates, and the CFO transition are largely keeping the stock in neutral territory while they refresh their models. As you read on, you will see how these pieces fit together and what to watch as the RxSight story continues to...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
TipRanks
Mar 21, 2026

Transformational Opportunities: UBS Suggests 2 Longevity Stocks to Buy as the $8T Aging Boom Accelerates

For years, the conversation around getting older has focused on individuals – retirement, lifestyle, healthcare. But a bigger story has been quietly unfolding in the background. The U.S. population itself is aging, and that shift is starting to ripple far beyond personal milestones. The Chief Investment Office at UBS views this trend as a foundation for long-term portfolio positioning. It frames “longevity” as a structural theme – a growing, aging population with evolving needs, particularly in

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Investing.com
Mar 21, 2026

How does the current decline in airline stocks compare to historical periods?

Investing.com -- Major U.S. airlines are approaching a critical inflection point as the industry grapples with a sudden spike in energy costs that threatens to upend full-year profitability. According to a research note from UBS, several carriers are expected to issue mid-quarter updates this week, with analysts predicting a widespread suspension of fiscal year 2026 guidance.

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Investing.com
Mar 21, 2026

Why is oil priced in dollars?

Investing.com -- The long-standing hegemony of the U.S. dollar in global energy markets is facing a structural reassessment as shifting trade patterns and military spending priorities among Gulf producers challenge the "petrodollar" status quo.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
TheStreet
Mar 21, 2026

UBS has a stark message for investors on S&P 500

The S&P 500 is having its worst weekly stretch in a year. Oil prices are surging. Iran war fears are rattling every asset class. Traders are now pricing in a 50% chance of a Fed rate hike by October. And yet UBS just told investors the index is going to 7,700 by year-end. That is roughly 17% ...

BEARISH
Negative press. News cycle fixated on risk factors or misses.